Heartflow to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
Rhea-AI Summary
Heartflow (Nasdaq: HTFL) will report fourth quarter and full year 2025 financial results after market close on March 18, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day with a live webcast and archived replay available for 12 months.
Investors must register to receive dial-in numbers and a unique PIN; participants are encouraged to register at least 15 minutes before the call.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
HTFL fell 16.55% while key peers were mostly up: PRVA +3.47%, BTSG +2.53%, HNGE +1.17%, PINC +0.07%. Only WAY declined 8.32%, indicating a stock-specific move rather than a sector-wide drop.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Registry expansion | Positive | -16.6% | Expanded GAMEFILM Registry to include former NBA and NHL players. |
| Jan 06 | Coverage expansion | Positive | +2.5% | Aetna added nationwide coverage for Heartflow Plaque Analysis across key plans. |
| Jan 05 | Conference participation | Positive | +2.5% | Management presented at the 44th J.P. Morgan Healthcare Conference. |
| Dec 18 | Guideline endorsement | Positive | +6.5% | ACC/AHA statements highlighted Heartflow-based pathways for CAD management. |
| Dec 11 | Outcomes and economics | Positive | +1.0% | Real‑world analyses in >90,000 patients showed prognostic power and cost savings. |
Recent fundamental and clinical news has mostly seen positive price alignment, but the latest GAMEFILM registry expansion drew a sharply negative reaction, indicating at least one notable divergence between positive news flow and share performance.
Over the last few months, HTFL reported several positive developments: large-scale FFRCT outcomes and cost-savings data on Dec 11, 2025, major guideline support for its Plaque Analysis on Dec 18, 2025, and expanded payer coverage including Aetna effective Dec 23, 2025. Earlier in 2026, the company highlighted J.P. Morgan conference participation and GAMEFILM registry expansion to additional professional athletes. Against this backdrop, today’s earnings-date scheduling update follows a period of generally constructive clinical and reimbursement news.
Market Pulse Summary
This announcement sets expectations for Heartflow’s fourth quarter and full-year 2025 results, scheduled for March 18, 2026 after the close, with a conference call at 1:30 p.m. PT / 4:30 p.m. ET. Set against recent clinical validation, expanded payer coverage, and notable insider and shareholder filings, investors may focus on how reported metrics and commentary compare with these prior developments and what management signals about growth, adoption, and capital needs.
AI-generated analysis. Not financial advice.
MOUNTAIN VIEW, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the fourth quarter and full year of 2025 after market close on Wednesday, March 18, 2026. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on March 18, 2026.
Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live and archived webcast of the event will also be available on the “Investor Relations” section of the Heartflow website at https://ir.heartflow.com. The archived version will be available for 12 months following completion of the live call.
About Heartflow’s Technology and Research
Heartflow’s technology is redefining precision cardiovascular care through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,400 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by ACC/AHA guidelines and supported by more than 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for over 500,000 patients worldwide.1 Key benefits include:
- Proprietary data pipeline: Built from more than 160 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible insights across diverse patient populations.
- Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 200 studies assessing over 365,000 patients. Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed
97% . - Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.
- Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001.
About Heartflow, Inc.
Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com.
Investor Contact
Nick Laudico
nlaudico@heartflow.com
Media Contact
Elliot Levy
elevy@heartflow.com
____________________
1Gulati, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation & Diagnosis of Chest Pain. J Am Coll Cardiol.
FAQ
When will Heartflow (HTFL) report Q4 and full year 2025 results?
What time is the Heartflow (HTFL) earnings conference call on March 18, 2026?
How can investors join the Heartflow (HTFL) March 18, 2026 webcast and replay?
Do I need to register to join the Heartflow (HTFL) March 18 earnings call?
Where will Heartflow (HTFL) post the earnings webcast and investor materials?
